Acquired amegakaryocytic thrombocytopenia after durvalumab administration

• Published in: Journal of Clinical and Experimental Hematopathology Vol. 61; no. 1; pp. 53 - 57
• Main Authors: Suyama, Takahiro, Hagihara, Masao, Kubota, Naoto, Osamura, Yoshiyuki, Shinka, Yoko, Miyao, Naoki
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society for Lymphoreticular Tissue Research 01.01.2021; JSLRT
• Subjects: acquired amegakaryocytic thrombocytopenia; Case Report; durvalumab; eltrombopag; immune checkpoint inhibitor; immune-related thrombocytopenia; acquired amegakaryocytic thrombocytopenia; immune-related thrombocytopenia; durvalumab; immune checkpoint inhibitor; eltrombopag

Immune checkpoint inhibitors (ICIs), despite their ability to potentiate antitumor T-cell responses, may cause various immune-related adverse events. Most cases of thrombocytopenia induced by ICIs have revealed a pathophysiologic mechanism of immune thrombocytopenia with increased platelet destructi...